Cilostazol
- Generic Name
- Cilostazol
- Drug Type
- Small Molecule
- Chemical Formula
- C20H27N5O2
- CAS Number
- 73963-72-1
- Unique Ingredient Identifier
- N7Z035406B
- Background
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
- Indication
Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
- Associated Conditions
- Intermittent Claudication
Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 848
- Registration Number
- NCT06530537
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Cilostazol and Aspirin in Stroke and TIA
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Incheon St.Mary's Hospital
- Target Recruit Count
- 378
- Registration Number
- NCT06522113
- Locations
- 🇰🇷
The Catholic university of korea, Incheon St. Mary's hospital, Incheon, Korea, Republic of
Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage
- Conditions
- ICH - Intracerebral Hemorrhage
- Interventions
- Procedure: Conventional internal medicine treatment
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06504576
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
- Conditions
- Fallopian Tube CarcinomaMalignant Solid NeoplasmMalignant Uterine NeoplasmVulvar CarcinomaCervical CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma
- Interventions
- Device: Cryocompression TherapyOther: Best PracticeOther: Quality-of-Life Assessment
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Emory University
- Target Recruit Count
- 70
- Registration Number
- NCT06492070
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
Clopidogrel Versus Cilostazol on Vessels
- Conditions
- Type 2 DiabetesAtherosclerosis
- Interventions
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT06402747
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
Clopidogrel Versus Cilostazol in Ischemic Stroke
- Conditions
- Ischemic Stroke
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 900
- Registration Number
- NCT06242132
- Locations
- 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt
Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke
- Conditions
- Ischemic Stroke
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 580
- Registration Number
- NCT06242145
- Locations
- 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt
Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke
- Conditions
- Ischemic Stroke
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 580
- Registration Number
- NCT06202755
- Locations
- 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt
Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA
- Conditions
- Ischemic Stroke
- Interventions
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 900
- Registration Number
- NCT06196047
- Locations
- 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt
BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers
- Conditions
- Intermittent Claudication
- Interventions
- Drug: PMR Tablet 145 mg
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Genovate Biotechnology Co., Ltd.,
- Target Recruit Count
- 40
- Registration Number
- NCT06167265
- Locations
- 🇺🇸
Cliantha Research, Saint Petersburg, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.